Not recruitingRare disease

Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

Verified siteInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Alport syndrome, a genetic condition that can lead to kidney disease, hearing loss, and eye abnormalities. The trial will test a medication called Vonafexor, which is taken as a tablet. The purpose of the study is to assess the safety and tolerability of Vonafexor in patients who are at risk of progression of Alport syndrome.

Participants in the study will receive Vonafexor in a fixed dose-escalation manner, meaning the dose may be gradually increased to find the most suitable level. Some participants may receive a placebo instead of the actual medication. The study will monitor the participants' health through regular check-ups, including physical examinations and laboratory tests, to observe any changes in their condition while on the treatment and after the treatment period ends.

The trial will also measure the levels of Vonafexor in the blood to ensure they match expected concentrations. This will help researchers understand how the medication is processed in the body. The study aims to provide valuable information on the potential benefits and any side effects of Vonafexor for people with Alport syndrome.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, the patient must have signed an informed consent form. This is a document that explains the study and confirms the patient's willingness to participate.
The patient must meet specific criteria, such as being between 18 and 55 years old, having a confirmed diagnosis of Alport syndrome, and having certain kidney function levels.
Step 2
Initial assessment
The patient undergoes an initial assessment to confirm eligibility. This includes tests for hepatitis B, hepatitis C, and HIV, as well as a review of medical history and current medications.
Step 3
Treatment phase
The patient begins taking vonafexor, which is administered orally in tablet form. The dosage and frequency are determined by the study protocol.
The treatment phase involves regular monitoring of the patient's health, including physical examinations, vital signs, and laboratory tests.
Step 4
Monitoring and evaluation
Throughout the treatment phase, the patient is monitored for any adverse effects. This includes tracking any new symptoms or changes in health status.
The patient's kidney function and vonafexor plasma levels are evaluated at specific intervals to assess the drug's impact.
Step 5
End of treatment
After completing the treatment phase, the patient stops taking vonafexor and continues to be monitored for a period to observe any changes in health status.
The study aims to assess the safety and tolerability of vonafexor both during and after treatment.
Step 6
Final assessment
A final assessment is conducted to evaluate the overall effects of the treatment. This includes a comparison of health indicators from before and after the study.

Who can join the trial?

10 criteria

The patient must have signed an informed consent form. If the patient is under eighteen in the United States, their legal representatives must also sign.
Sexually active females who can have children and sexually mature males must agree to use two effective methods of birth control during the study and for at least 6 weeks after the last dose.
The patient must test negative for hepatitis B, hepatitis C, and HIV.
The patient must be between 18 and 55 years old. In the United States, patients as young as 16 can participate.
The patient must have a confirmed diagnosis of **Alport Syndrome**. This can be through clinical signs like blood in urine, family history, hearing loss, or eye changes, or through a kidney biopsy showing specific changes. Genetic confirmation is also required.
The patient must have an **eGFR** (a measure of kidney function) between 30 and less than 90 ml/min/1.73m².
The patient must have increased **albuminuria**, which means a **UACR** (urine albumin-to-creatinine ratio) of 300 mg/g or higher.
If the patient is taking an **ACE inhibitor** or **ARB** (medications for blood pressure and kidney protection), they should have been on a stable and well-tolerated dose for at least 60 days before the study starts.
If the patient is taking **SGLT2** (a type of medication for diabetes and kidney protection), they should have been on a stable and well-tolerated dose for at least 60 days before the study starts.
If the patient has a history of high blood pressure, they should be on stable treatment for at least 60 days before the study starts, and their blood pressure should be controlled according to the study investigator.

Who cannot join the trial?

4 criteria

Patients who are not diagnosed with Alport Syndrome cannot participate. Alport Syndrome is a genetic condition that affects the kidneys, ears, and eyes.
Patients who are not at risk of progression of Alport Syndrome cannot participate. This means the condition is not expected to get worse over time.
Patients who are younger than 18 years old cannot participate.
Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like pregnant women, children, or people who cannot make decisions for themselves.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Assistance Publique Hopitaux De Marseille
Verified
Marseille, France
Centre Hospitalier Universitaire De Bordeaux
Verified
Bordeaux, France
Centre Hospitalier Universitaire De Montpellier
Verified
Montpellier, France

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Vonafexor is being studied to see if it is safe and well-tolerated in patients with Alport syndrome who are at risk of disease progression. The trial aims to understand how patients respond to the medication both while they are taking it and after they stop.

Vonafexor

What is already known about the treatment

Vonafexor – Vonafexor is administered orally and is currently being studied in clinical trials for its safety and effectiveness in treating Alport Syndrome, a genetic condition affecting the kidneys. The medication is in the investigational stage, with ongoing research to determine its potential benefits and risks. It is primarily indicated for patients at risk of progression of Alport Syndrome. At the molecular level, vonafexor works by modulating specific pathways that may help in reducing kidney damage associated with the syndrome. It is classified pharmacologically as a selective modulator, targeting specific receptors to achieve its therapeutic effects.

Investigated diseases

Alport Syndrome – Alport Syndrome is a genetic disorder that primarily affects the kidneys, ears, and eyes. It is characterized by progressive kidney disease, hearing loss, and eye abnormalities. The condition is caused by mutations in genes responsible for producing type IV collagen, a protein essential for the normal function of the basement membranes in these organs. Over time, individuals with Alport Syndrome may experience worsening kidney function, leading to chronic kidney disease. Hearing loss typically begins in childhood or adolescence and can progress to significant impairment. Eye changes may include anterior lenticonus and retinal flecks, which can affect vision.